Why is reported revenue growth (10.4%) so much higher than organic growth (3.0%)?

The gap reflects acquisitions and one-time items. The Advanced Patient Monitoring business (acquired via Edwards Lifesciences' Critical Care unit in September 2024) contributed about $278M of inorganic revenue in the quarter. Prior-year revenue also included roughly $67M of Italian payback and legal accruals, which BD excludes from its adjusted figures. Organic growth strips out both effects and is the better measure of underlying demand.

Did BD's underlying business improve, and is the EPS guidance raise credible?

Profitability improved meaningfully: GAAP operating income rose 46.6% and gross margins expanded. However, the EPS raise is driven partly by margin gains and cost discipline rather than top-line acceleration, since organic growth of 3.0% was flat with the reaffirmed full-year guidance. Management also flagged incremental Q4 selling and marketing investment, which could pressure near-term margins. Investors should watch whether organic growth accelerates sequentially, as management has said it intends.

What does the Waters transaction mean for BD shareholders?

BD agreed to combine its Biosciences and Diagnostic Solutions units with Waters Corporation, creating a life science and diagnostics company focused on regulated, high-volume testing. Management frames the deal as capturing synergies and leaving 'New BD' as a more focused medical technology company. The filing notes the deal may not close as described or at all, and that the transaction carries execution and timing risks. These two units produced declining revenue in the quarter, so their transfer could change BD's growth and margin profile.

Are there balance sheet or cash flow concerns?

Cash flow weakened: nine-month operating cash flow declined to $2.08B from $2.67B, largely due to a $942M working capital and other outflow. Cash and equivalents fell to $735M from $1.7B, and long-term debt stands at $17.5B. Dividends ($899M) and buybacks ($750M) exceeded the reduction in free cash flow over the period, so the company drew down cash. Investors should monitor whether operating cash flow recovers in the fourth quarter and whether leverage stays manageable while the company pursues the Waters deal.

Which segments are driving performance, and which are lagging?

BD Medical is the largest contributor, with reported growth of 14.4%, though organic growth was only 3.2%, and the Advanced Patient Monitoring acquisition accounts for much of the reported increase. BD Interventional grew 7.2% (6.8% FXN, 6.8% organic), led by Urology & Critical Care (PureWick) and Peripheral Intervention (Rotarex). BD Life Sciences declined 0.5% reported, with Diagnostic Solutions down on point-of-care and BACTEC weakness and Biosciences dragged by instrument demand, partially offset by growth in Specimen Management.

BDX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 7, 2025. Cited figures are marked; the original filing is the authoritative source.

BD (Becton, Dickinson and Company) reported fiscal Q3 2025 results (quarter ended June 30, 2025) that beat on margin and EPS.

Reported revenue rose 10.4% to $5.5 billion^a, while organic growth was a more modest 3.0%. Growth was inflated by the Advanced Patient Monitoring (Critical Care from Edwards) acquisition, which contributed about $278 million of inorganic revenue. Adjusted revenue grew 8.9% (8.5% FX-neutral) after excluding roughly $67 million of prior-year-related Italian medical device payback and legal accruals in the comparison base.

GAAP operating income rose 46.6% to $882 million^b, and GAAP gross margin expanded 160 basis points to 47.8%. Adjusted gross margin rose 50 basis points to 54.8%, and adjusted operating income grew 11.3% to $1.42 billion. Profitability was the bright spot.

GAAP diluted EPS was $2.00^c, up 19.0%, and adjusted diluted EPS was $3.68, up 5.1% (4.6% FX-neutral). Management raised full-year FY2025 adjusted EPS guidance to $14.30–$14.45 from $14.06–$14.34, about 9.4% growth at the midpoint, and reaffirmed organic revenue growth of 3.0%–3.5%. Management noted that incremental selling and marketing investment is planned for Q4, which may temper the margin trajectory.

Segment performance was mixed: BD Medical grew 14.4% reported but only 3.2% organically, Interventional grew 7.2%, and Life Sciences declined 0.5% (organic -1.1%), with Biosciences and Diagnostic Solutions weak. The balance sheet and cash flow warrant attention. Nine-month operating cash flow fell to $2.08 billion^d from $2.67 billion, with working capital and other items a drag of $942 million.

The company repurchased $750 million of stock in the nine months and expects to complete the remaining $250 million of its $1 billion buyback by fiscal year-end. Cash fell to $735 million from $1.7 billion, and long-term debt was $17.5 billion. Management also announced a definitive agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corporation, which is a key strategic event that remains subject to closing risk.

02—Key points

Key Highlights

Reported Q3 revenue of $5.509B grew 10.4% (8.5% adjusted FXN), but organic growth was only 3.0%, with the difference driven largely by the Advanced Patient Monitoring acquisition ($278M inorganic revenue).
GAAP gross margin expanded 160 bps to 47.8%, and adjusted gross margin rose 50 bps to 54.8%, supported by BD Excellence productivity initiatives.
GAAP diluted EPS of $2.00 rose 19.0%, while adjusted diluted EPS of $3.68 grew 5.1% (4.6% FX-neutral), with GAAP operating income up 46.6% to $882M.
FY2025 adjusted EPS guidance raised to $14.30–$14.45 (about 9.4% growth at midpoint, +$0.18), while organic revenue growth guidance of 3.0%–3.5% was reaffirmed.
Segment divergence: BD Medical grew 14.4% reported but only 3.2% organically; BD Interventional grew 7.2%; BD Life Sciences declined 0.5% with Biosciences and Diagnostic Solutions weak.
Nine-month operating cash flow fell to $2.08B from $2.67B, and cash declined to $735M, while the company returned capital through $750M of buybacks and $899M in dividends.
Announced definitive agreement to combine Biosciences & Diagnostic Solutions with Waters Corporation, a major portfolio transformation that remains subject to closing risk and execution.

03—Questions

Frequently Asked Questions

Why is reported revenue growth (10.4%) so much higher than organic growth (3.0%)?
The gap reflects acquisitions and one-time items. The Advanced Patient Monitoring business (acquired via Edwards Lifesciences' Critical Care unit in September 2024) contributed about $278M of inorganic revenue in the quarter. Prior-year revenue also included roughly $67M of Italian payback and legal accruals, which BD excludes from its adjusted figures. Organic growth strips out both effects and is the better measure of underlying demand.
Did BD's underlying business improve, and is the EPS guidance raise credible?
Profitability improved meaningfully: GAAP operating income rose 46.6% and gross margins expanded. However, the EPS raise is driven partly by margin gains and cost discipline rather than top-line acceleration, since organic growth of 3.0% was flat with the reaffirmed full-year guidance. Management also flagged incremental Q4 selling and marketing investment, which could pressure near-term margins. Investors should watch whether organic growth accelerates sequentially, as management has said it intends.
What does the Waters transaction mean for BD shareholders?
BD agreed to combine its Biosciences and Diagnostic Solutions units with Waters Corporation, creating a life science and diagnostics company focused on regulated, high-volume testing. Management frames the deal as capturing synergies and leaving 'New BD' as a more focused medical technology company. The filing notes the deal may not close as described or at all, and that the transaction carries execution and timing risks. These two units produced declining revenue in the quarter, so their transfer could change BD's growth and margin profile.
Are there balance sheet or cash flow concerns?
Cash flow weakened: nine-month operating cash flow declined to $2.08B from $2.67B, largely due to a $942M working capital and other outflow. Cash and equivalents fell to $735M from $1.7B, and long-term debt stands at $17.5B. Dividends ($899M) and buybacks ($750M) exceeded the reduction in free cash flow over the period, so the company drew down cash. Investors should monitor whether operating cash flow recovers in the fourth quarter and whether leverage stays manageable while the company pursues the Waters deal.
Which segments are driving performance, and which are lagging?
BD Medical is the largest contributor, with reported growth of 14.4%, though organic growth was only 3.2%, and the Advanced Patient Monitoring acquisition accounts for much of the reported increase. BD Interventional grew 7.2% (6.8% FXN, 6.8% organic), led by Urology & Critical Care (PureWick) and Peripheral Intervention (Rotarex). BD Life Sciences declined 0.5% reported, with Diagnostic Solutions down on point-of-care and BACTEC weakness and Biosciences dragged by instrument demand, partially offset by growth in Specimen Management.

04—Continue

← View all 8-K filings